Introduction
The suprachiasmatic nucleus (SCN), located in the anterior hypothalamus, receives direct entraining photic input from the retina through glutamate release from retinohypothalamic tract (RHT) terminals [1, 2] . Retinorecipient cells stimulated by RHT signaling are believed to release vasoactive intestinal polypeptide (VIP) to help synchronize SCN pacemaker cell activity to the lightdark cycle (LD) [3] . Evidence supporting such an action of VIP consists of findings that intra-SCN administration of VIP at night induces per1 and per2 clock gene expression and causes phase-shifts in clock timing in a manner similar to that produced by light exposure [4, 5] . In addition, mice lacking VIP display circadian activity similar to wild types under LD, but are arrhythmic under constant darkness (DD), and those lacking functional VIP (VPAC 2 ) receptors do not maintain circadian rhythmicity under LD and lack the rhythmic expression of per1 and per2 [6] .
Despite this information, little is known with regard to the nature of in-vivo VIP regulation. This knowledge gap largely stems from the lack of information on synaptic VIP release in the SCN. The aim of this study, therefore, was to undertake brain microdialysis assessments of VIP in the hamster SCN to characterize its 24-h release profile under LD and DD. We also assessed the effects of stimulations with photic phase-resetting stimuli [light pulse and intra-SCN N-methyl-D-aspartate (NMDA) treatment]. Further, given the modulatory role of serotonin (5-HT) in SCN photic signaling, the effect of intra-SCN treatment with (±)8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide (8-OH-DPAT), a 5-HT 1A,7 receptor agonist, on VIP release was also explored.
Methods

Animals
Adult male Syrian hamsters (Mesocricetus auratus) were maintained in a climate-controlled environmental chamber (20-221C) under a 14 : 10 L : D photoperiod (200-250 lux illuminance). Rodent chow (Prolab 3000; PMI Feeds Inc., St Louis, Missouri, USA) and water were provided ad libitum. Before experimentation animals were acclimated to a circular polycarbonate cage (Raturn; Bioanalytical Systems Inc., West Lafayette, Indiana, USA). The experiments were approved by the Kent State Institutional Animal Care and Use Committee and were conducted using the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
Suprachiasmatic nucleus microdialysis
The microdialysis procedures used are similar to those described in earlier studies on SCN neuropeptide release [7, 8] . Animals received a probe implant (CMA/12; 20 kDa cutoff; CMA Microdialysis Inc., North Chelmsford, Massachusetts, USA) with the tip aimed at the lateral margin of the SCN (coordinates: AP: + 0.03 from bregma, L: + 0.04 from midline, H: -0.80 from dura; head level). After 48 h of recovery, artificial cerebral spinal fluid (ACSF) was perfused through the probe at a rate of 1.0 ml/min. The microdialysate samples were frozen at -701C until analysis. Probe tip placement was verified histologically at the end of the experiment (probe tip placement diagrammed in Fig. 1 ).
Suprachiasmatic nucleus microdialysate neuropeptide measurements
The content of VIP in SCN microdialysate was measured by radioimmunoassay (Phoenix Pharmaceuticals Inc., Burlingame, California, USA). The assay is highly specific for VIP, with low cross-reactivity of the primary antibody with other peptides (data supplied with the kit, RK-064-16). The assay sensitivity was approximately 0.2 pg, with an IC 50 of 159 pg/ml. The intraassay coefficient of variability was 11.7% and the typical peptide yield was approximately 2.0-60.0 pg/sample.
Circadian locomotor activity measurements
In experiments measuring 24 h profiles of VIP release under LD (n = 7) and DD (n = 5), general locomotor activity rhythms were monitored 4-5 days before, during, and 2 weeks after microdialysis sampling to verify a normal pattern of circadian behavioral activity, and to establish subjective circadian time (CT) under DD.
Experimental protocols Validation of neuronal vasoactive intestinal polypeptide release
Two separate intra-SCN reverse-dialysis experiments were performed to verify that the VIP collected in microdialysate samples was from neuronal release. First, SCN VIP release was measured after a 1 h pulse of depolarizing medium consisting of ACSF with high [K + ] (150 mM) and veratridine, a sodium channel-activator [100 mM; Sigma (Sigma Chemical Co., St Louis Missouri, USA); n = 4]. Second, a calcium channel-blocking cocktail [diltiazem, 200 mM; verapamil, 200 mM; cinnarizine, 15 mM; flunarizine, 12 mM in Ca 2 + -free ACSF with EDTA (10 mM), n = 4] was similarly administered. For both trials, microdialysis was initiated 2 days after probe implantation starting with a 2 h equilibration period, followed sequentially by a 1 h baseline collection with normal ACSF, a 1 h pulse of depolarizing or Ca 2 +blocking medium, and a 2 h postdrug sample collection with normal ACSF. Controls using normal ACSF were run in parallel (n = 7).
Daily profile of SCN VIP release under LD and DD
Two days after probe implantation, the probe lining was connected to a syringe pump at Zeitgeber time (ZT) 4 (LD; n = 7) or CT 4 (DD; n = 5) and perfusion with ACSF was initiated. After a 2 h equilibration period, sample collection was initiated at ZT 6 or CT 6 and continued over a 24 h period. The automated fraction collector was set with a time delay to account for the lag-time of effluent flow from the probe to reach the collector. Microdialysis probe implantation under DD was undertaken by anesthetizing animals in the darkness and masking the eyes with black tape to prevent photic stimulation during surgery. The microdialysis procedures, including probe connection, were undertaken under dim red light (0.5 lux).
Photic and nonphotic treatment effects on suprachiasmatic nucleus peptide release
Here photic (light and glutamatergic) and nonphotic (serotonergic) mechanisms regulating VIP release were evaluated. Two days after probe implantation microdialysis was initiated and hamsters underwent 2 h of equilibration with normal ACSF. This was followed by a 1 h baseline collection that preceded a 1 h light pulse (approximately 280 lux; ZT 13-14; n = 4), or 1 h reverse dialysis perfusion with NMDA (200 mM; ZT 13-14; n = 3), or 8-OH-DPAT (1.2 mM; ZT 6-7; n = 4) in ACSF followed by 2-3 h of posttreatment sampling.
Statistics
Drug effects were normalized as a percentage of the pretreatment baseline collections and were analyzed by repeated measures of analysis of variance. Treatment effects were determined using a post-hoc Student Newman-Keuls test. Individual 24 h profiles of VIP release were normalized by expressing values as a percentage of the daily mean. Daily variations in this release were analyzed as in the earlier experiments [9] using repeated measures of analysis of variance followed by Dunnet's test procedure for comparing multiple group means [10] . For all procedures the level of significance was set at P less than 0.05. 
Results
Neuronal release of vasoactive intestinal polypeptide from the suprachiasmatic nucleus Synaptic VIP release was confirmed by local suppression of SCN neurons with reverse-dialysis perfusion of ACSF containing Ca 2 + blockers. This treatment acutely decreased VIP release over pretreatment baseline levels [55 ± 8% of baseline; F(4,19) = 3.846; P = 0.019 vs. baseline; Fig. 2a ]. In contrast, similar perfusion with a depolarizing medium of high [K + ] ACSF with veratridine stimulated VIP release [199 ± 28%; F(7,11) = 5.111; P < 0.001 vs. baseline; Fig. 2b ].
Daily profiles of vasoactive intestinal polypeptide release from the suprachiasmatic nucleus Release under light-dark cycle
The output of VIP from the SCN was rhythmic under LD, with maximal release near midday [211 ± 19% of the daily mean; F(6,23) = 2.291; P = 0.002; Fig. 3a ]. Output was low at lights-on but rose sharply to an acrophase at ZT 5. Thereafter, output quickly dropped and remained low through the remainder of the day and most of the night to a nadir at ZT 16 (75 ± 9% of the daily mean).
Release under constant darkness
Under DD, VIP release was arrhythmic. No discernable rhythmic pattern of release was evident [F(2,23) = 1.581; P = 0.092; Fig. 3b ].
Photic and nonphotic (serotonergic) effects on SCN VIP release Light pulse
A 1 h light pulse delivered in the early night (ZT 13-14) caused an acute increase in VIP release from the SCN lasting the duration of the stimulation [342 ± 117% of baseline levels; F(6,14) = 3.539; P < 0.001; Fig. 4a ].
N-methyl-D-aspartate
A 1 h reverse microdialysis perfusion with the glutamate agonist, NMDA, in the early night (ZT 13-14) caused an increase in VIP release from the SCN spanning the duration of drug perfusion, and lasting approximately 1 h posttreatment [335 ± 62% of baseline; F(6,13) = 6.2 65; P < 0.001; Fig. 4b ].
( ± )8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide A 1 h reverse microdialysis perfusion with the 8-OH-DPAT, 5-HT 1A,7 agonist, in midday caused a decrease in the VIP release throughout the duration of the drug perfusion, and extended for at least 2 h posttreatment [24 ± 12% of pretreatment baseline; F(7,14) = 3.317; P = 0.001; Fig. 4c ].
Discussion
Photic input to the SCN is essential for synchronizing circadian clock time to the external LD cycle. On the basis of several lines of evidence, VIP is implicated as a mediator of this process, as light induces c-Fos expression in SCN cells containing VIP and VIP microinjection into the SCN can reset the clock in a manner similar to that of light [11, 12] . However, to date little is known about the regulatory nature of VIP activity in the SCN, as its release from the SCN has never been measured in vivo.
Our results show that under LD VIP is rhythmically released from the hamster SCN, with peak release at midday. This is temporally consistent with observations that VIP mRNA in the rat SCN is highest 4 h before the lights are on, followed by peak levels of VIP-like immunoreactivity approximately 2-6 h later [13] . Although it is uncertain how daily changes in neuropeptide immunoreactivity may reflect a diurnal pattern of release, these microdialysis assessments of VIP in the extracellular fluid compartment offer a clear picture of the rhythmic nature of synaptically-released peptide. The concept that SCN VIP neuronal activity is driven by photic (RHT) input is supported by several observations from this study. First, the daily fluctuation in VIP release seen under LD is lost under DD. This fits with the earlier studies where VIP-like immunoreactivity did not vary in animals in DD [14] . Second, light exposure at night increases SCN VIP release. This is consistent with the finding that light also increases per gene expression in VIP-containing neurons [15] . Third, localized perfusion of the SCN with NMDA at night stimulates VIP release with maximal levels (approximately 300% of baseline) similar in magnitude to those induced by photic stimulation (the more prolonged rise induced by the NMDA was possibly because of longer time of clearance of the drug vs. endogenous glutamate). Notably, NMDA also increases VIP release in the SCN slice during the early subjective night [16] . The function of the photically-induced increase in VIP release could be to provide photic input to oscillator cells, as VIP neurons project to arginine vasopressin-expressing pacemaker neurons of the dorsal SCN shell region [17] . Possibly the midday peak in VIP is a critical cue for pacemaker neuron phase control.
Serotonergic actions in the SCN are also well documented, with 5-HT particularly implicated in the negative modulation of photic phase-shifting responses. For instance, increasing 5-HT by administering selective reuptake inhibitors attenuates light-induced phase-shifts [18] and systemic administration of 8-OH-DPAT, the 5-HT 1A,7 agonist, abolishes light-induced Fos expression in the SCN and attenuates light-induced phase shifts in activity rhythms [19] . In contrast, inhibiting serotonergic signaling with 5-HT receptor antagonists enhances photic shifting [20] . As VIP neurons likely participate in the SCN photic signaling cascade as retinorecipient units [21] , and receive innervation from serotonergic fibers [22] , it is feasible that their activity could be attenuated by 5-HT. This idea is consistent with this finding that SCN VIP release is strongly suppressed by 8-OH-DPAT. This effect implicates 5-HT 1A and/or 5-HT 7 receptors in mediating this response, which is supported by reports that postsynaptic 5-HT 7 receptors inhibit SCN photic signaling [23, 24] . It is also important to note that a presynaptic inhibitory photic effect mediated by SCN 5-HT 1B receptors has also been reported [25] , but this does not preclude the aforementioned postsynaptic action(s) of 5-HT.
Conclusion
The in-vivo circadian pattern of VIP release from the SCN of hamsters was characterized for the first time using microdialysis. A circadian rhythm of release was expressed under LD, but was abolished under DD. Photic regulation of VIP release was also verified by findings that neuropeptide release was stimulated by nocturnal light and NMDA treatments. Finally, VIP is inhibited by serotonergic activation, suggesting a possible mode for the attenuating action of 5-HT in SCN photic signaling. Collectively, these results indicate a role for VIP in the maintenance of circadian rhythms with respect to environmental lighting, and point to a mechanism for 5-HT in the processing of SCN photic input.
